These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36138068)

  • 1. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).
    Gavriilaki E; Labopin M; Sakellari I; Salmenniemi U; Yakoub-Agha I; Potter V; Berceanu A; Rambaldi A; Hilgendorf I; Kröger N; Mielke S; Zuckerman T; Sanz J; Busca A; Ozdogu H; Anagnostopoulos A; Savani B; Giebel S; Bazarbachi A; Spyridonidis A; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Dec; 57(12):1803-1809. PubMed ID: 36138068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).
    Gavriilaki E; Sakellari I; Labopin M; Bornhäuser M; Hamladji RM; Casper J; Edinger M; Zák P; Yakoub-Agha I; Ciceri F; Schroeder T; Zuckerman T; Kobbe G; Yeshurun M; Narni F; Finke J; Diez-Martin JL; Berceanu A; Hilgendorf I; Verbeek M; Olivieri A; Savani B; Spyridonidis A; Nagler A; Mohty M
    Bone Marrow Transplant; 2023 Oct; 58(10):1084-1088. PubMed ID: 37420011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.
    Shimoni A; Labopin M; Savani B; Hamladji RM; Beelen D; Mufti G; Socié G; Delage J; Blaise D; Chevallier P; Forcade E; Deconinck E; Mohty M; Nagler A
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):751-757. PubMed ID: 29247780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Socie G; Kroeger N; Blaise D; Veelken H; Bermudez A; Or R; Lioure B; Beelen D; Fegueux N; Hamladji RM; Nagler A; Mohty M
    Leuk Res; 2015 Sep; 39(9):933-7. PubMed ID: 26003666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT.
    Swoboda R; Labopin M; Giebel S; Schroeder T; Kröger N; Arat M; Savani B; Spyridonidis A; Hamladji RM; Potter V; Berceanu A; Yakoub-Agha I; Rambaldi A; Ozdogu H; Sanz J; Nagler A; Mohty M
    Bone Marrow Transplant; 2023 Mar; 58(3):282-287. PubMed ID: 36460819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
    J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
    Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
    Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
    Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
    J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
    Duque-Afonso J; Finke J; Labopin M; Craddock C; Protheroe R; Kottaridis P; Tholouli E; Byrne JL; Orchard K; Salmenniemi U; Hilgendorf I; Hunter H; Nicholson E; Bloor A; Snowden JA; Verbeek M; Clark A; Savani BN; Spyridonidis A; Nagler A; Mohty M
    Bone Marrow Transplant; 2022 Aug; 57(8):1269-1276. PubMed ID: 35568756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
    Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older.
    Kawamura K; Kako S; Mizuta S; Ishiyama K; Aoki J; Yano S; Fukuda T; Uchida N; Ozawa Y; Eto T; Iwato K; Kanamori H; Kahata K; Kondo T; Sawa M; Ichinohe T; Atsuta Y; Kanda Y
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2079-2087. PubMed ID: 28890406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT.
    Bug G; Labopin M; Niittyvuopio R; Stelljes M; Reinhardt HC; Hilgendorf I; Kröger N; Kaare A; Bethge W; Schäfer-Eckart K; Verbeek M; Mielke S; Carlson K; Bazarbachi A; Spyridonidis A; Savani BN; Nagler A; Mohty M
    Bone Marrow Transplant; 2023 Jun; 58(6):710-716. PubMed ID: 37002412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
    Sheth V; Labopin M; Canaani J; Volin L; Brecht A; Ganser A; Mayer J; Labussière-Wallet H; Bittenbring J; Shouval R; Savani B; Mohty M; Nagler A
    Bone Marrow Transplant; 2019 Apr; 54(4):531-539. PubMed ID: 30087463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
    Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.
    Lüftinger R; Zubarovskaya N; Galimard JE; Cseh A; Salzer E; Locatelli F; Algeri M; Yesilipek A; de la Fuente J; Isgrò A; Alseraihy A; Angelucci E; Smiers FJ; La La Nasa G; Zecca M; Fisgin T; Unal E; Kleinschmidt K; Peters C; Lankester A; Corbacioglu S;
    Ann Hematol; 2022 Mar; 101(3):655-665. PubMed ID: 34999929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.